Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (DE:DUL)
FRANKFURT:DUL
Holding DE:DUL?
Track your performance easily
DUL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€132.70 - €276.90
Previous Close€228.1
Volume0.00
Average Volume (3M)40.00
Market Cap
€29.54B
Enterprise Value€28.13B
Total Cash (Recent Filing)$2.78B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Feb 06, 2025EPS Estimate
-€0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.62
Shares Outstanding128,980,917
10 Day Avg. Volume24
30 Day Avg. Volume40
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)912.40
Price to Sales (P/S)14.71
Price to Cash Flow (P/CF)176.20
P/FCF Ratio194.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.43
Enterprise Value/Gross Profit18.53
Enterprise Value/Ebitda-152.50
Forecast
1Y Price Target
€302.10Price Target Upside32.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
Alnylam Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsVutrisiran demonstrated robust benefits on outcomes in the Ph3 HELIOS-B study, even with a mild patient population on substantial background therapy.
Pipeline StrengthAlnylam benefits from a deep and well-diversified RNAi portfolio in multiple disease populations with four FDA/EMA-approved drugs in rare diseases and two partnered drugs with blockbuster potential.
Regulatory ApprovalFDA acceptance of the sNDA for vutrisiran in TTR amyloidosis cardiomyopathy is announced, indicating progress for ALNY.
Bears Say
Market ChallengesAmvuttra is either not covered or 'effectively' not covered in several Medicare segments, disadvantaged in MAPD & non-Medicare, and advantaged in Medigap-related segments.
Product Development IssuesDevelopment of ALN-KHK, an RNAi therapeutic targeting ketohexokinase for type 2 diabetes, has been suspended.
Regulatory ConcernsAn advisory committee meeting is not planned, a concern due to ALNY's recent track record with the Agency and last-minute changes.
---
DUL FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was €132.70 and its highest was €276.90 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Feb 06, 2025 which is in 46 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Oct 31, 2024. The company reported -€0.828 earnings per share for the quarter, beating the consensus estimate of -€0.873 by €0.045.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -€0.54.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 128,980,910 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -€0.828 in its last earnings report, beating expectations of -€0.873. Following the earnings report the stock price went down -1.801%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 996M.
---
Alnylam Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€302.10 (32.44% Upside)
€302.10 (32.44% Upside)
Blogger Sentiment
Bullish
DE:DUL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.53%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
DUL Company Deck
---
DUL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The overall sentiment of the earnings call reflects a positive outlook driven by strong revenue growth, significant advancements in the pipeline, and successful regulatory submissions. Despite some challenges such as decreased collaboration revenue and the discontinuation of a development program, the highlights, including record revenue growth and promising pipeline progress, significantly outweigh the lowlights.Read More>---
DUL Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
DUL Stock 12 Month Forecast
Average Price Target
€302.10
▲(32.44% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Moderna
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Best Analysts Covering DUL
1 Year
1 Year Success Rate
22/30 ratings generated profit
1 Year Average Return
+28.14%
assigned a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +28.14% per trade.
---